Medullary Thyroid Carcinoma
20
3
4
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.0%
1 terminated out of 20 trials
88.9%
+2.4% vs benchmark
10%
2 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (20)
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
PET-TC in Thyroid Evaluation
Spanish Study for Molecular Characterization of Thyroid Carcinoma
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC
Collection of Tissue Samples for Study of Multidrug Resistance
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors